- Teva deal vs TMD: generics vs patented. huge difference.
- Mitra deal vs TMD: both patented but Mayne did heavy lifting for launch which is still trying to find its foot in the market. TMD products well established with ~$80m rev stream and fair life left on patent.
That's how I see huge difference in past failed acquisitions/licensing vs TMD licensing. Furthermore, consider when these products come off patent, Mayne will have upper hand in introducing its own generic version with all those HCP and relationships established over next couple of years. the exit point looks quite good and fits well with Maynes business model
Ann: MYX signs license agreement for women's health products, page-115
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |